



(12) Translation of
European patent specification

(11) NO/EP 3307267 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/42 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.09.09
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.04.10
(86)	European Application Nr.	17735004.8
(86)	European Filing Date	2017.06.09
(87)	The European Application's Publication Date	2018.04.18
(30)	Priority	2016.06.10, WO, PCT/EP16/063368
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ME
(73)	Proprietor	Oryzon Genomics, S.A., Carrera de San Jerónimo 15 2nd floor, 28014 Madrid, Spania
(72)	Inventor	MAES, Tamara, Oryzon Genomics S.A.Sant Ferran 74, 08940 Cornellà De Llobregat, Spania MASCARÓ CRUSAT, Cristina, Oryzon Genomics S.A.Sant Ferran 74, 08940 Cornellà De Llobregat, Spania ROTLANT POZO, David, Oryzon Genomics S.A.Sant Ferran 74, 08940 Cornellà De Llobregat, Spania
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54)	Title	MULTIPLE SCLEROSIS TREATMENT
(56)	References Cited:	WO-A1-2012/013728 EP-A1- 2 258 865 LAUREN G FRIEDMAN ET AL: "Meeting report on the Alzheimer's Drug Discovery Foundation 14th International Conference on Alzheimer's Drug Discovery", ALZHEIMERS RES THER, vol. 6, no. 2, 1 January 2014 (2014-01-01) , page 22, XP055403322, London, UK ISSN: 1758-9193, DOI: 10.1186/alzrt252 A. SCOU MANNE ET AL: "The Lysine-specific Demethylase 1 Is Required for Cell Proliferation in Both p53-dependent and -independent Manners", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 282, no. 21, 4 April 2007 (2007-04-04), pages 15471-15475, XP055229388, US ISSN: 0021- 9258, DOI: 10.1074/jbc.M701023200 BUESA CARLOS ET AL: "The dual lsd1/maob inhibitor ory2001 prevents the development of the

memory deficit in samp8 mice through induction of neuronal plasticity and reduction of neuroinflammation", ALZHEIMER'S & DEMENTIA: THE JOURNAL OF THE ALZHEIMER'S ASSOCIATION, vol. 11, no. 7, July 2015 (2015-07), XP029355257, ISSN: 1552-5260, DOI: 10.1016/J.JALZ.2015.08.146

Oryzon: "ORYZON presented new preclinical data of ORY-2001 therapeutic activity in Multiple Sclerosis at ACTRIMS-2017 ORY-2001 Reduces Lymphocyte Egress and Demyelination in Experimental Autoimmune Encephalomyelitis Data highlights the Epigenetic Axis in Multiple Sclerosis", , 27 February 2017 (2017-02-27), XP055403304, Retrieved from the Internet: URL:https://www.oryzon.com/sites/default/files/PRESS_RELEASE_10-2017.pdf [retrieved on 2017-09-01]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelse som er (-) 5-((((trans)-2-(4-(benzyloksy)fenyl)syklopropyl)amino)metyl)-1,3,4-oksadiazol-2-amin eller et
5 farmasøytisk akseptabelt salt eller solvat derav for anvendelse i behandling av
multippel sklerose.
2. Forbindelse for anvendelse ifølge krav 1, hvor multippel sklerose er kronisk
10 progressiv multippel sklerose.
3. Forbindelse for anvendelse ifølge krav 1, hvor forbindelsen er (-) 5-((((trans)-2-(4-(benzyloksy)fenyl)syklopropyl)amino)metyl)-1,3,4-oksadiazol-2-amin.
4. Forbindelse for anvendelse ifølge et hvilket som helst av kravene 1 eller 3, hvor
15 forbindelsen skal administreres oralt.
5. Forbindelse for anvendelse ifølge et hvilket som helst av kravene 1, 3 eller 4, hvor
pasienten som skal behandles er et menneske.
- 20 6. Forbindelse ifølge krav 2, hvor forbindelsen er (-) 5-((((trans)-2-(4-(benzyloksy)fenyl)syklopropyl)amino)metyl)-1,3,4-oksadiazol-2-amin.
7. Forbindelse for anvendelse ifølge krav 2 eller 6, hvor forbindelsen skal
administreres oralt.
- 25 8. Forbindelse for anvendelse ifølge et hvilket som helst av kravene 2, 6 eller 7, hvor
pasienten som skal behandles er et menneske.